3rd Edition of Cardiology World Conference

September 14-15, 2022 | Virtual Event

September 14 -15, 2022 | Online Event
Cardio 2022

Pericarditis is the most frequent post-COVID-19 complication and colchicine is a drug of choice

Sekib Sokolovic, Speaker at Cardiovascular Diseases Events
Sarajevo University Clinical Center, Bosnia and Herzegowina
Title : Pericarditis is the most frequent post-COVID-19 complication and colchicine is a drug of choice

Abstract:

INTRODUCTION: The post-COVID-19 syndrome is a subacute chronic condition affecting certain recovered patients from the acute viral infection. The most post-covid symptoms resolve after 3 months, but some patients experience continuation of fatigue, shortness of breath, palpitations, cough and muscle chest pain. That patients fall into category of long-covid syndrome.
METHOD: The prospective clinical randomized study of long-covid patients were included in the study.  Three groups of recovered patients were formed with mild (Group I) , moderate (Group II) and severe (Group III) clinical manifestation during acute covid-19 infection. Diagnostic procedures included the electrocardiogram, transthoracic echocardiography, magnetic resonance imaging (MRI) in a selected patients with risk factors and comorbidities analyzed.  Total of 192 post-covid-19 patients were included in this study.
RESULTS: The average duration of post-covid-19 symptoms was 16 weeks. Total of 106 females (55,2 %)and 86 (44,8%) males were observed with average age of 57,3 years. The most frequent manifestation was mild to moderate subacute pericarditis in 21,8% patients in average, but with a significant difference in all three groups.  The most often pericarditis was seen in a group III (77,4%), followed by group II (18,6,0%)%) and insignificant in a group I (4,0%). All patients received colchicine therapy that proved to be effective in all. MRI was performed in 6 patients and no myocarditis was found.
CONCLUSION: Our results indicate that Pericarditis is the most underlying condition in a long covid-19 period and colchicine could play a role on the therapy and prevention of recurrent pericarditis in the management  of complications associated with post-COVID-19 syndrome.
Key words: Long-Covid 19, Pericarditis, Colchicine

What will audience learn from your presentation?
Post-COVID-19 is real life and require objective investigation and therapy. This lecture will help audience to gain  knowledge about underlying conditions that are responsible for the long-COVID-19 symptoms. The fatigue is not only un-important symptom. There must be explanation for that.
Currently, practitioners do not treat specifically post-Covid-19 symptoms and do not use specific required therapy. They will now use the colchicine and other medications, with a strong anti-inflammatory property, in a these recovered, but long-covid patients.
Other faculty could use this research and our experience to expand their research or teaching as well.
This approach provide a practical solution to a Long-Covid-19 problem that could simplify or make a practitioner daily practice more efficient.
This will assist to the accuracy of a design of new research.
The most benefit goes to patients that will recover rapidly from the long-covid.

Biography:

Prof. Dr. Sekib Sokolovic studied Medicine at the Sarajevo University, Bosnia and Herzegovina and graduated in 1983. He  received his PhD degree in 2004 at the same institution.  He obtained the position of an Professor in Internal Medicine, Cardiology, Vascular Disease and Rheumatology at the same institution. He gained subspecialty training in Rheumatology at University of California Irvine, L.A. and later subspecialty in Cardiology at Medical Faculty of Sarajevo. He has published research articles in SCI(E) journals.), reviewer of many scientific journals worldwide and invited speaker at domestic and international medical scientific conferences and symposia. 

Watsapp